Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

Original publication

DOI

10.1371/journal.pmed.1001259

Type

Journal article

Journal

PLoS medicine

Publication Date

01/2012

Volume

9

Addresses

timothy.hallett@imperial.ac.uk

Keywords

HIV Modelling Consortium Treatment as Prevention Editorial Writing Group, Humans, HIV Infections, Antiretroviral Therapy, Highly Active, Decision Making, Evidence-Based Medicine, Models, Biological, Clinical Trials as Topic